Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients

  • New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2] 
  • Additional data at WCD show the consistent negative health impact and economic burden of CSU, including anxiety, depression, impact on work ability and health system costs[3],[4] 
  • CSU is a severe skin condition with symptoms such as persistent itching, swelling and a rash that spontaneously presents and re-occurs for more than six weeks[5]-[7]

Basel, 12 June 2015 - Novartis announced today new analyses from pivotal Phase III registration studies showing Xolair® (omalizumab) helps patients with Chronic Spontaneous Urticaria (CSU) achieve significant improvements in quality of life measures. These findings were presented at the 23rd World Congress of Dermatology (WCD) in Vancouver, Canada.

  • The Dermatology Life Quality Index (DLQI), which gives a total score from 0-30, from best to worst QoL, whereby a score of >11 signifies that CSU/CIU has a very large to extremely large effect on a patient`s life.
  • The Chronic Urticaria Quality of Life questionnaire (CU-Q2oL), which measures urticaria-specific QoL (total score from 0-100, from best to worst QoL).
  • Xolair: DLQI - 73-78%; CU-Q2oL - 66-69%.
  • Placebo: DLQI - 22-47%; CU-Q2oL - 32-42%.